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epidemiology
Primary cutaneous lymphomas (PCL) are defined as non-
Hodgkin lymphomas that present in the skin with no evidence
of extracutaneous disease at the time of diagnosis. After the
gastro-intestinal lymphomas, PCL are the second most
common group of extranodal non-Hodgkin lymphomas with
an estimated annual incidence of 1/100 000. PCL must be
distinguished from nodal or systemic malignant lymphomas
involving the skin secondarily, which often display other
clinical behaviour, have a different prognosis and require
a different therapeutic approach. In recent lymphoma
classifications PCL are therefore included as separate entities.
Within the group of PCL distinct types of cutaneous T-cell
lymphoma (CTCL) and cutaneous B-cell lymphoma (CBCL)
can be distinguished. In Europe, CTCL constitute about
75–80% of all PCL, CBCL 20–25%, but different distributions
have been observed in other parts of the world.
diagnosis
The diagnosis and classification of PCL should always be
based on a combination of clinical, histological and
immunophenotypical data. Demonstration of clonal TCR or Ig
gene rearrangements in lesional skin or peripheral blood may be
a valuable adjunct in selected cases. However, clinical features are
the most important decision makers for therapeutic planning.
PCL should be classified according to the criteria of the World
Health Organization–European Organization for Research and
Treatment of Cancer (WHO–EORTC) classification.
staging
In all cases, except for patients with early stage mycosis
fungoides (MF) or its variants and patients with lymphomatoid
papulosis adequate staging should be performed to exclude
the presence of extracutaneous disease. Adequate staging
includes complete physical examination, complete and
differential blood cell count and serum biochemistry,
appropriate imaging techniques and optionally a bone marrow
biopsy and aspirate. Prognosis is extremely variable depending
on the type of PCL and the stage of disease. For clinical
staging of MF and Se´zary syndrome (SS) the revised TNM
staging system should be used. For PCL other than MF/SS
a separate TNM classification system has recently been
published. This staging system is primarily meant to document
extent of disease and cannot be used as a prognostic guide.
therapy
The choice of treatment depends on the type of PCL and the
stage of disease. Due to their heterogeneity and rarity, controlled
clinical trials in PCL are almost non-existent, with few
exceptions mainly concerning recently marketed drugs.
Recommendations are therefore largely based on (retrospective)
cohort studies and expert opinions discussed during consensus
meetings of the EORTC Cutaneous Lymphoma Group and the
International Society for Cutaneous Lymphomas (ISCL).
mycosis fungoides and variants
Since early aggressive chemotherapy is associated with
considerable side effects, but does not improve survival, a stage-
adapted conservative therapeutic approach is recommended for
MF and its variants. In patients with limited patches and
plaques topical steroids or even a watch and wait policy can be
advised. In patients with more extensive patches and plaques
(stage IB) skin-directed therapies including topical steroids,
PUVA (psoralens + UVA), narrow band UVB (only for
patches) and topical cytostatic agents, such as mechlorethamine
or carmustine (BCNU), can be used. In patients developing one
or few tumors (stage II) additional local radiotherapy
suffices. Local radiotherapy can be curative in patients with
localized disease and in patients with pagetoid reticulosis. In
patients with more extensive plaques and tumors or patients
refractory to skin-directed therapies, a combination of PUVA
and interferon or PUVA and retinoids, including bexarotene,
or total skin electron beam irradiation can be considered.
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In relapsed disease, alternative approaches (denileukin
diftitox, varinostat) may be applied. Multiagent chemotherapy
is only indicated in patients with effaced lymph nodes or
visceral involvement (stage IV), or in patients with widespread
tumor stage MF that cannot be controlled with skin-targeted
and immunomodulating therapies.
Sezary syndrome
Being a systemic disease (leukemia) by definition, systemic
treatment is required. Skin-directed therapies like PUVA or
potent topical steroids may be used as adjuvant therapy.
Extracorporeal photopheresis (ECP), either alone or in
combination with other treatment modalities, has been
suggested as the treatment of choice in SS and erythrodermic
MF, with overall response rates of 30–80%, and complete
response rates of 14–25%. However, the suggested superiority
of ECP over the traditional low-dose chemotherapy regimens
has not yet been substantiated by controlled randomized
trials. Prolonged treatment with a combination of low-dose
chlorambucil and prednisone is often effective in controlling
the disease, but is unlikely to give complete responses. Low-
dose methotrexate, bexarotene, multi-agent chemotherapy
and alemtuzumab have been recommended as second-line
treatment for SS. Alternative approaches include varinostat
and histon deacetylase inhibitors (especially in erythrodermic
stages). It should be emphasized that comparison of
treatment results in the diffeent studies is almost
impossible, because of differences in diagnostic criteria used
for SS.
primary cutaneous CD30-positive
lymphoproliferative disorders
The group of primary cutaneous CD30-positive
lymphoproliferative disorders (LPD) includes primary
cutaneous anaplastic large lymphoma (C-ALCL) and
lymphomatoid papulosis (LyP), which form a spectrum of
disease. Patients with C-ALCL generally present with solitary or
localized (ulcerating) tumors or nodules and should be treated
with radiotherapy or surgical excision. Patients presenting
with multifocal skin lesions can best be treated with
radiotherapy in case of only a few lesions, or with low dose
methotrexate as in LyP. Multi-agent chemotherapy is only
indicated in patients presenting with or developing
extracutaneous disease and rare patients with rapidly
progressive skin disease.
subcutaneous panniculitis-like T-cell
lymphoma (SPTL)
The term SPTL is nowadays only used for cases with an a/b
T-cell phenotype, which have an excellent prognosis
particularly if not associated with a hemophagocytic syndrome,
which is frequently an extremely aggressive clinical syndrome
requiring immediate intervention. A recent study reports
a 5-year overall survival of 91% and 46% in SPTL patients
without and with a HPS, respectively. In SPTL without
associated HPS systemic steroids or other immunosuppressive
agents are recommended, whereas in cases of solitary skin
lesions radiotherapy is advised. Only in progressive disease not
responding to immunosuppressive therapy or HPS multi-agent
chemotherapy should be considered.
extranodal NK/T-cell lymphoma, nasal type
Extranodal NK/T-cell lymphoma, nasal type is a nearly always
Epstein–Barr virus-positive lymphoma, which characteristically
presents with a midfacial ulceronecrotic tumor and
uncommonly at other skin sites. These lymphomas have an
aggressive clinical course and should be treated with combined
chemotherapy. In patients presenting with a solitary skin
lesion and ineligible for systemic chemotherapy, radiotherapy
should be considered.
Table 1. WHO–EORTC classification
Cutaneous T-cell lymphoma Cutaneous B-cell lymphoma
Mycosis fungoides (MF) Primary cutaneous marginal zone B-cell lymphoma
Variants of MF Primary cutaneous follicle centre lymphoma
Folliculotropic MF Primary cutaneous diffuse large B-cell lymphoma, leg type
Pagetoid reticulosis
Granulomatous slack skin
Se´zary syndrome
Primary cutaneous CD30-positive lymphoproliferative disorders
Primary cutaneous anaplastic large cell lymphoma
Lymphomatoid papulosis
Subcutaneous panniculitis-like T-cell lymphoma
Extranodal NK/T-cell lymphoma, nasal-type
Primary cutaneous peripheral T-cell lymphoma, NOS
Aggressive epidermotropic CD8+ CTCLa
Cutaneous c/d T-cell lymphomaa
CD4+ small/medium-sized pleomorphic CTCLa
aProvisional entities.
NOS, not otherwise specified; CTCL, cutaneous T-cell lymphoma.
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primary cutaneous peripheral T-cell lymphoma,
not otherwise specified (PTL, NOS)
Within the group of primary cutaneous PTL, NOS three
subgroups have been included as provisional entities (see
Table 1). However, all cases have in common a generally
aggressive clinical course and a poor survival, and should
therefore be treated with multi-agent chemotherapy.
Since the results are often disappointing, early allogeneic
stem cell transplantation may be considered. The only
exception is the group of CD4-positive small-medium
pleomorphic CTCL. These patients, often presenting with
a solitary tumor, preferentially on the head, should be
treated with local radiotherapy or excision and have an
excellent prognosis.
cutaneous B-cell lymphoma
In the WHO–EORTC classification three main types of CBCL
are distinguished: primary cutaneous marginal zone
lymphoma (PCMZL), primary cutaneous follicle centre
lymphoma (PCFCL) and primary cutaneous diffuse large
B-cell lymphoma, leg type (PCLBCL-LT). PCMZL and
PCFCL are indolent types of CBCL with a disease-related
10-year-survival exceeding 90%, while PCLBCL-LT has
a more unfavourable prognosis (disease-related 5-year
survival, 50%). Recently, EORTC/ISCL consensus
recommendations for the management of these three types of
CBCL have been formulated, which are summarized in
Table 2. Treatment options vary significantly in intensity and
should be applied according to performance status and
comorbidity.
follow-up
The frequency of follow-up visits depends on the type of PCL
and stage of disease. It may vary from every 6–12 months in
patients with indolent PCL and at least stable disease to every
4–6 weeks in patients with active or progressive disease.
Follow-up visits should focus on history and physical
examination, and additional testing (histology, blood
examination, imaging, etc) should only be performed if
required.
note
Levels of evidence [I–V] and grades of recommendation [A–D]
as used by the Americal Society of Clinical Oncology are given
in square brackets. Statements without grading were considered
justified standard clinical practice by the experts and the ESMO
Faculty.
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